Drugs / MA09-hRPE
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01625559 | Sep 2012 → Apr 2015 | Stargardt disease | CHABiotech CO., Ltd | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT02122159 | Mar 2013 → Jul 2016 | myopic macular degeneration | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01674829 | Sep 2012 → Sep 2017 | dry age related macular degeneration | CHABiotech CO., Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01469832 | Dec 2011 → Sep 2015 | Stargardt disease | Astellas Institute for Regenerative Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01345006 | Jun 2011 → Aug 2015 | Stargardt disease | Astellas Institute for Regenerative Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01344993 | Jun 2011 → Aug 2015 | dry age related macular degeneration | Astellas Institute for Regenerative Medicine | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02563782 Comparator | Aug 2015 → May 2017 | dry age related macular degeneration | Astellas Institute for Regenerative Medicine | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MA09-hRPE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01674829 ↗ |
| Known as | hESC Derived RPE | “Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy” NCT01345006 ↗ |
| Modality | Cell therapy | “retinal pigment epithelium (RPE) cellular therapy” NCT01344993 ↗ |
| Route | Other | “subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells” NCT01344993 ↗ |